Immune response that protects against infections also drives HIV latency

An immune response that likely evolved to help fight infections appears to be the mechanism that drives human immunodeficiency virus (HIV) into a latent state, lurking in cells only to erupt anew, researchers at Duke Health report.

Wearable maker ActiGraph acquires assets from Biofourmis to boost clinical trial offerings

ActiGraph, a maker of wearables and software used by drug companies in clinical trials, on Tuesday announced it acquired the life sciences business of Biofourmis,

January 7, 2025

Q32 Bio’s stock crashes after atopic dermatitis fail, alopecia trial snafu

After a mid-stage failure in atopic dermatitis, Q32 Bio plans to take bempikibart forward in alopecia instead, despite a trial in that indication also coming

December 12, 2024

FDA commissioner: Health systems have to ‘step up’ on AI regulation or will ‘end up holding the bag’

WELLESLEY, Mass. — Amid heated discussions on how artificial intelligence should be regulated and who should be involved in health care AI governance, the U.S.

September 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.